Tom Tamberrino
Vermögen: 331 290 $ am 30.06.2026
Vermögen: 331 290 $ am 30.06.2026
Tom Tamberrino is Chief Commercial Officer at Profound Medical Corp.
since 2024.
Formerly, Mr. Tamberrino was Managing Partner at Silver Oak Properties LLC from 2018 to 2024, Vice President-Sales & Marketing at Novadaq Technologies, Inc. from 2017 to 2018, and Area Director at LifeCell Corp.
from 2010 to 2012.
Education includes an MBA from Emory University and an undergraduate degree from Georgetown University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PROFOUND MEDICAL CORP 0,14 % | 24.06.2026 | 49.818 ( 0,14 % ) | 331 290 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PROFOUND MEDICAL CORP. | Corporate Officer/Principal | 14.10.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
Silver Oak Properties LLC | Corporate Officer/Principal | 01.10.2024 |
| NOVADAQ TECHNOLOGIES INC. | Vertrieb & Marketing | 01.01.2018 |
LifeCell Corp.
LifeCell Corp. BiotechnologyHealth Technology Develops and markets tissue repair products | Corporate Officer/Principal | 01.12.2012 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
LifeCell Corp.
LifeCell Corp. BiotechnologyHealth Technology Develops and markets tissue repair products | Health Technology |
Novadaq Technologies, Inc.
Novadaq Technologies, Inc. Medical SpecialtiesHealth Technology Develops and manufactures real-time fluorescence imaging products | Health Technology |
Emory University
Emory University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Silver Oak Properties LLC | |
Profound Medical Corp.
Profound Medical Corp. Medical SpecialtiesHealth Technology Develops and markets medical devices focused on prostate cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen